Editas Reports Q4 Earnings Beat

Genome editing company exceeds Wall Street expectations

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Editas Medicine Inc., a genome editing company based in Cambridge, Massachusetts, reported a loss of $5.6 million in its fourth quarter, surpassing Wall Street expectations. The company posted revenue of $24.7 million in the period, also exceeding analysts' forecasts.

Why it matters

Editas is a leading player in the rapidly growing field of genome editing, which has significant implications for medicine, agriculture, and other industries. The company's ability to exceed financial expectations signals its strong performance and potential for future growth.

The details

Editas reported a loss of 6 cents per share in the fourth quarter, better than the average estimate of a 27-cent loss per share from six analysts surveyed by Zacks Investment Research. The company also posted revenue of $24.7 million, surpassing the $6.5 million expected by four analysts surveyed by Zacks.

  • Editas reported its Q4 earnings on Monday, March 9, 2026.

The players

Editas Medicine Inc.

A genome editing company based in Cambridge, Massachusetts.

Got photos? Submit your photos here. ›

The takeaway

Editas' strong financial performance in Q4 2026 demonstrates the company's ability to execute and capitalize on the growing demand for genome editing technologies, positioning it for continued success in the rapidly evolving field.